ACRAL MELANOMA
Clinical trials for ACRAL MELANOMA explained in plain language.
Never miss a new study
Get alerted when new ACRAL MELANOMA trials appear
Sign up with your email to follow new studies for ACRAL MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New STING agonist drug enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests the safety of CRD3874-SI, a drug that activates the STING pathway to boost the immune system against cancer. About 81 adults with advanced solid tumors (sarcoma, Merkel cell carcinoma, and others) will receive weekly IV infusions at increasing doses. …
Matched conditions: ACRAL MELANOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cancer, and give them back after a short course of chemotherapy. T…
Matched conditions: ACRAL MELANOMA
Phase: PHASE1 • Sponsor: Anusha Kalbasi • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Blood tests could predict melanoma treatment success
Knowledge-focused Recruiting nowThis study enrolls 200 people with acral or cutaneous melanoma who are starting standard immunotherapy. Researchers will collect blood samples every 3 weeks and tumor tissue after about 3 months of treatment. By analyzing circulating tumor cells, DNA, and other markers, they aim …
Matched conditions: ACRAL MELANOMA
Sponsor: Xijing Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC